Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.23.1
Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Payroll and incentives $ 510 $ 1,705
General and administrative expenses 186 455
Research and development expenses 95 130
Deferred revenue * [1] 721
Other deferred liabilities ** [2] 88
Total $ 791 $ 3,099
[1] At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 was related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).
[2] At December 31, 2022, the balances of $88 was related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).